If You Build It, They Will Come' - Prof Kelly Chibale features in The Medicine Maker for founding the first Drug Discovery and Development Centre (H3D) in Africa. He was also included in the magazine's 2020 Power List. See list here: https://themedicinemaker.com/power-list/2020
20 000 South African women marched to the Union Buildings in Pretoria on this day in 1956 to protest the pass laws which required women of colour to carry a passport during the apartheid era.
We are pleased to advise that the H3D Symposium has been rescheduled for 10-12 March 2021, Spier Conference Centre, Stellenbosch, Cape Town.
To register or for more information, please visit the symposium website. Should you require any assistance with your existing or new registration, please do not hesitate to contact our Secretariat Office on: +27 21 9101913 / email@example.com
We look forward to seeing you in March 2021
The Organising Committee
The African Academy of Sciences (AAS), through its Grand Challenges Africa programme, The Drug Discovery and Development Centre (H3D) at the University of Cape Town (UCT), Medicines for Malaria Venture (MMV) and the Bill and Melinda Gates Foundation (BMGF) came together in 2018 to expand and strengthen the drug discovery community in Africa.
The first cohort of eight drug discovery scientists was successfully awarded in June 2019, after a rigorous selection process.
Interested to be a part of the next phase of support for the drug discovery call 2020? Please apply here through the AAS website.Article credit: AAS. (https://www.aasciences.africa/calls/grand-challenges-africa-round-10-2nd-drug-discovery-call)
H3D's Dr John Woodland discusses repurposing antimalarial drugs, such as chloroquine, as viable treatment options in the fight against COVID-19.
Kelly Chibale, Founder and Director of H3D and Neville Isdell Chair, and Nina Lawrence, Senior Investigator, presented at the J.C. Flowers Foundation’s Isdell:Flowers Cross Border Malaria Initiative’s 2020 Round Table on February 27th and 28th in Livingstone, Zambia. The duo, who spoke on a panel discussing scientific highlights in the field of malaria elimination, described the importance of developing new medicines for malaria elimination and eradication with an African-centric design.
UCT’s Drug Discovery and Development Centre (H3D) aims to bring new medicines “from the bench to the bedside”. But how acquainted are prospective healthcare professionals with the difficulties of developing new treatments? Conversely, are research scientists aware of the challenges faced by medical professionals at the frontline of public healthcare in South Africa? These were the questions that the second collaboration between H3D and SHAWCO Health, UCT’s student-run community outreach organisation, sought to address.
Recently, H3D hosted a lunch in honour of Mr Neville Isdell to thank him for his generosity and leadership. Mr Isdell donated approximately R18 million towards the establishment of a five-year Neville Isdell Chair in African-centric Drug Discovery and Development at H3D.
Antimicrobial resistance (AMR) has been an ongoing threat to public health in South Africa as well as other countries in Africa. Disturbingly, the burden in the continent from infectious diseases has also been on the rise. Part of the reason is the persistence of infections associated with tropical regions as well as the higher rates of poverty and greater spread of drug resistance.